
- /
- Supported exchanges
- / US
- / FGEN.NASDAQ
FibroGen Inc (FGEN NASDAQ) stock market data APIs
FibroGen Inc Financial Data Overview
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get FibroGen Inc data using free add-ons & libraries
Get FibroGen Inc Fundamental Data
FibroGen Inc Fundamental data includes:
- Net Revenue: 6 996 K
- EBITDA: -94 375 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: 0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
FibroGen Inc News

FibroGen To Implement 1-for-25 Reverse Stock Split
(RTTNews) - FibroGen, Inc. (FGEN) on Thursday announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock, effective June 16, 2025. FibroGen's common st...


FibroGen to implement 1-for-25 reverse stock split; shares down 15%
* FibroGen (NASDAQ:FGEN [https://seekingalpha.com/symbol/FGEN]) will execute a 1-for-25 reverse stock split effective June 16, 2025, at 5:00 p.m. ET. * Trading on a split-adjusted basis will begin...

FibroGen Announces 1-for-25 Reverse Stock Split
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reve...

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. “Michael i...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.